Alto Neuroscience’s Post

Listen in as our CEO Amit Etkin and NAMI Montana executive director Matt Kuntz discuss how we are combatting trial-and-error in #psychiatry through our precision drug development approach and patient advocacy initiatives in this NBC Montana segment: https://bit.ly/3XR05e3

#DYK that the prevalence of major depressive episodes is highest among individuals who report having multiple (two or more) races? This National #MinorityMentalHealth Awareness Month let's raise awareness and break the stigma around #MentalHealth in minority communities. Check out this episode of NAMI's podcast discussing the importance of minority mental health: https://bit.ly/4btXKsr #ShadesofMentalHealth

We are excited to share that our company is now included in the Russell 2000® Index and Russell 3000® Index, effective today! Learn more about this milestone and the Russell Indexes: https://lseg.group/4eLqu2M #RussellReconstitution $ANRO

Our team had a blast getting together for Alto's annual summer event. Between the engaging Town Hall meeting, breakout discussions, team-building activities, and socializing after work, the Alto core value of #InThisTogether was well represented this week. Until next time! 🎉

Meet Priyanka Takle, an Alto Clinical Scientist. Priyanka has been on the team since day one, evaluating study sites, reviewing data from ongoing trials, and supporting patient recruitment. When she's not working, Priyanka enjoys hiking, reading, baking, and skiing! #MeetTheTeam

Our Precision Psychiatry Platform™ leverages the richest human data sets and is built on a decade of clinical #neuroscience research. Constantly iterating on what we discover, our platform enables us to harness the power of #AI driven brain #biomarkers to match patients with the right Alto drugs in development. Learn more about our platform here: https://bit.ly/4efTm32

We're pleased to announce the initiation of our Phase 2 study of ALTO-101, a novel PDE4 inhibitor in development for the treatment of cognitive impairment associated with #schizophrenia. Learn more here: https://bit.ly/4etQaAW

🏆 We are proud to share that our CEO, Amit Etkin, has been named a 2024 EY Entrepreneur Of The Year Bay Area winner! This prestigious award recognizes his visionary leadership, innovation, and unwavering commitment to catalyzing meaningful change in #MentalHealth treatment through #PrecisionPsychiatry. We look forward to continued growth at Alto under his guidance. Read more here: https://bit.ly/45LB3z3

👥 The past few decades have seen stunning medical breakthroughs, but very little progress has been made in #MentalHealth. Every person’s brain reacts to medications differently, which is why taking a #PrecisionPsychiatry approach, where each patient is matched with the right Alto drug in development for their unique biology, is vital for creating meaningful impact. See how we're working to redefine #psychiatry: https://bit.ly/3z6wWRu